TP53 and hepatocellular carcinoma: Their study further revealed that Oroxylin A (CDK9 inhibitor) suppressed SIRT1 phosphorylation, reduced p53 deacetylation and restored its acetylation and activity, ultimately inhibiting HCC progression.